Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination With Other Antiretroviral Agents in People Living With HIV

NCT04143594 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT04143594
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04143594 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination With Other Antiretroviral Agents in People Living With HIV
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Completed
Start date
November 22, 2019
Completion date
September 19, 2023
Enrollment
183 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection